New Study by Yale University Raises Concerns About E-Cigarettes

News by 2FIRSTS.ai
Aug.13.2024
New Study by Yale University Raises Concerns About E-Cigarettes
Yale study reveals some e-cigarettes may contain potent nicotine-like chemicals, raising health concerns beyond FDA regulation.

According to a report by Newsweek on August 12, a previous study by Yale University found that some e-cigarettes may contain chemical compounds similar to nicotine that could have unknown effects on health.


These nicotine alternatives interact with receptors in the brain, without being subject to FDA restrictions and regulations. As a result, these products are able to be marketed with flavors that appeal to young people and avoid tobacco taxes.


An FDA spokesperson stated that these new chemicals may be more potent than nicotine and could potentially affect the brain development, learning abilities, and memory of adolescents.


FDA Public Affairs Specialist Jim McKinney told Newsweek that...


The FDA is addressing this issue from the perspective of the entire agency and will continue to utilize all resources within its authority to protect the public, especially American adolescents, from potentially harmful addictive products.


McKinney points out that, although more research is needed, some emerging data suggests that these nicotine analogs may be more potent than nicotine itself, which is already highly addictive, altering adolescent brain development and producing long-term effects.


According to research, nicotine analogs are chemical substances that are structurally very similar to nicotine and therefore target the same receptors in the brain. Examples include 6-methyl nicotine and nicotineamide. A study in rodents suggests that 6-methyl nicotine may be more toxic than nicotine. Furthermore, because these compounds are not subject to the same strict regulations as traditional nicotine, the ingredients listed on labels may not always match the actual ingredients in the products.


Dr. Hanno Erythropel, a scientist at the Yale School of Medicine, stated in a press release,


In conclusion, the company is actually trying to evade regulation by introducing new products containing nicotine analogues with unknown health and addiction risks.


In a study published in the journal "JAMA Network," the researcher and their colleagues analyzed two e-cigarette and e-liquid products on the market. The first product, Spree Bar, claimed to contain 5% of 6-methyl nicotine (50 milligrams/gram), while the second product, Nic-Safe, was tested at four concentrations—0, 12, 24, and 36 milligrams/milliliter.


The research results show that both products do not contain the ingredients as specified on their labels. Spree Bar actually contains 90% less 6-methyl nicotine than advertised, while Nic-Safe contains a low concentration of 6-methyl nicotine without it being clearly marked on the label (excluding tested nicotine-free products).


FDA spokesperson Mackinney said that


In general, the FDA does not comment on specific studies, but instead uses them as part of the evidence to further understand specific issues and help achieve its mission of protecting public health. Regarding nicotine mimetics, the FDA is aware that some companies are reported to be producing products that may contain compounds with chemical structures or properties different from nicotine.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
Why AIRSCREAM Built its European Production Hub for Regulated Market Growth
AIRSCREAM’s production hub in the Czech Republic brings nicotine pouch manufacturing, e-liquid bottling, product documentation, warehousing and international logistics into one operation, giving brands and commercial partners a practical platform from which to launch, expand and enter new markets.
Market
Sep.16 by 2Firsts Perspectives
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippines Weighs Unified Vape Tax as Lawmakers Back Risk-Based Rates and Government Seeks to Fill ₱66 Billion Revenue Gap
Philippine lawmakers are considering an overhaul of the country's vape excise-tax regime to eliminate the wide gap between taxes on nicotine salt and freebase nicotine liquids and reduce incentives for misdeclaration. House Bill 5364, filed by Rep. Rufus Rodriguez and Rep. Maximo Rodriguez Jr., would impose a unified ₱10-per-milliliter tax on vapor products, with 5% annual increases beginning in 2027. Rodriguez says the proposal could generate an average ₱6 billion in annual collections from 2027 through 2030. The debate comes as the Philippine government considers tobacco, vape and other health-tax reforms to help offset around ₱66 billion in revenue expected to be forgone under a proposed tax-relief package.
Aug.18
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
GSTHR Estimates 200 Million People Use Non-Combustible Nicotine Products as 28 Countries Show Rising Use Alongside Falling Smoking Rates
The Global State of Tobacco Harm Reduction, a project operated by Knowledge·Action·Change, estimates that about 200 million people worldwide use non-combustible nicotine products including vapes, heated tobacco, nicotine pouches and snus. Its 2026 report says use of these products rose alongside declining smoking rates in 28 countries it analyzed. The data do not establish that all 200 million users have quit smoking, nor do they prove a direct causal relationship. GSTHR also says regulatory restrictions on the products continue to expand in many markets.
Sep.10